Literature DB >> 27091417

Palliative Chemotherapy Affects Aggressiveness of End-of-Life Care.

Chin-Chia Wu1, Ta-Wen Hsu2, Chun-Ming Chang3, Cheng-Hung Lee4, Chih-Yuan Huang5, Ching-Chih Lee6.   

Abstract

INTRODUCTION: Although palliative chemotherapy during end-of-life care is used for relief of symptoms in patients with metastatic cancer, chemotherapy may lead to more aggressive end-of-life care and less use of hospice service. This is a population-based study of the association between palliative chemotherapy and aggressiveness of end-of-life care. PATIENTS AND METHODS: Using the National Health Insurance Research Database of Taiwan, we identified 49,920 patients with metastatic cancer who underwent palliative chemotherapy from January 1, 2009, to December 31, 2011. Patients who received chemotherapy 2-6 months before death were included. Aggressiveness of end-of-life care was examined by previously reported indicators. Cardiopulmonary resuscitation and endotracheal tube intubation were included as indicators of aggressive end-of-life care. The association between palliative chemotherapy and hospice care was studied.
RESULTS: Palliative chemotherapy was associated with more aggressive treatment. After adjustment for patient age, sex, Charlson Comorbidity Index score, cancer group, primary physician's specialty, postdiagnosis survival, hospital characteristics, hospital caseload, urbanization, and geographic regions, more than one emergency room visit (p < .001), more than one intensive care unit admission (p < .001), and endotracheal intubation (p = .02) during end-of-life care were significantly more common in patients receiving palliative chemotherapy. Patients who did not receive palliative chemotherapy received more hospice care in the last 6 months of life (p < .001).
CONCLUSION: Although the decision to initiate palliative chemotherapy was made several months before death, this study showed that palliative chemotherapy was associated with more aggressive end-of-life care, including more emergency room visits and intensive care unit admissions, and endotracheal intubation. The patients who received palliative chemotherapy received less hospice service toward the end of life. IMPLICATIONS FOR PRACTICE: Palliative chemotherapy is used for patients with incurable cancer toward the end of life (EOL). Aggressiveness of EOL care and hospice care are related to the quality of life of these patients. This study of data from the Taiwanese National Health Insurance Research Database found that palliative chemotherapy led to more aggressive EOL care and less hospice care. There is a need to provide patients with terminal cancer access to care information that best meets their needs, especially those patients who receive palliative chemotherapy. ©AlphaMed Press.

Entities:  

Keywords:  Aggressiveness of cancer treatment; End-of-life care; Palliative chemotherapy

Mesh:

Year:  2016        PMID: 27091417      PMCID: PMC4912365          DOI: 10.1634/theoncologist.2015-0445

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  40 in total

1.  Evolution of Taiwan's health care system.

Authors:  Jui-Fen Rachel Lu; Tung-Liang Chiang
Journal:  Health Econ Policy Law       Date:  2010-03-04

2.  Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer.

Authors:  C Doyle; M Crump; M Pintilie; A M Oza
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

3.  Chemotherapy near the end of life.

Authors:  Michael W Rabow
Journal:  BMJ       Date:  2014-03-04

4.  Congruence of knowledge, experiences, and preferences for disclosure of diagnosis and prognosis between terminally-ill cancer patients and their family caregivers in Taiwan.

Authors:  Siew Tzuh Tang; Tsang-Wu Liu; Mei-Shu Lai; Li-Ni Liu; Chen-Hsiu Chen; Shin-Lan Koong
Journal:  Cancer Invest       Date:  2006 Jun-Jul       Impact factor: 2.176

5.  Trends in the aggressiveness of end-of-life cancer care in the universal health care system of Ontario, Canada.

Authors:  Thi H Ho; Lisa Barbera; Refik Saskin; Hong Lu; Bridget A Neville; Craig C Earle
Journal:  J Clin Oncol       Date:  2011-03-14       Impact factor: 44.544

6.  Quality of end-of-life care in patients with hematologic malignancies: a retrospective cohort study.

Authors:  David Hui; Neha Didwaniya; Marieberta Vidal; Seong Hoon Shin; Gary Chisholm; Joyce Roquemore; Eduardo Bruera
Journal:  Cancer       Date:  2014-02-18       Impact factor: 6.860

7.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

8.  The Lisbon Challenge: acknowledging palliative care as a human right.

Authors:  Lukas Radbruch; Sheila Payne; Liliana de Lima; Diederik Lohmann
Journal:  J Palliat Med       Date:  2013-01-31       Impact factor: 2.947

9.  Equal cancer treatment regardless of education level and family support? A qualitative study of oncologists' decision-making.

Authors:  Nina Cavalli-Björkman; Bengt Glimelius; Peter Strang
Journal:  BMJ Open       Date:  2012-08-24       Impact factor: 2.692

10.  Associations between palliative chemotherapy and adult cancer patients' end of life care and place of death: prospective cohort study.

Authors:  Alexi A Wright; Baohui Zhang; Nancy L Keating; Jane C Weeks; Holly G Prigerson
Journal:  BMJ       Date:  2014-03-04
View more
  10 in total

1.  Duration of palliative care involvement and immunotherapy treatment near the end of life among patients with cancer who died in-hospital.

Authors:  Juline Auclair; Stéphane Sanchez; Jan Chrusciel; Louise Hannetel; Matthieu Frasca; Guillaume Economos; Raphaelle Habert-Dantigny; Eduardo Bruera; Benoit Burucoa; Fiona Ecarnot; Isabelle Colombet; Cécile Barbaret
Journal:  Support Care Cancer       Date:  2022-02-22       Impact factor: 3.603

2.  End-of-life care in cancer patients: how much drug therapy and how much palliative care? Record linkage study in Northern Italy.

Authors:  Giulio Formoso; Massimiliano Marino; Monica Guberti; Roberto Giuseppe Grilli
Journal:  BMJ Open       Date:  2022-05-06       Impact factor: 3.006

3.  Advance directives and intensity of care delivered to hospitalized older adults at the end-of-life.

Authors:  Marsha H Tyacke; Jill L Guttormson; Mauricio Garnier-Villarreal; Kathryn Schroeter; Wendy Peltier
Journal:  Heart Lung       Date:  2019-09-03       Impact factor: 2.210

4.  The impact of initial treatment strategy and survival time on quality of end-of-life care among patients with oesophageal and gastric cancer: A population-based cohort study.

Authors:  Karin Dalhammar; Marlene Malmström; Maria Schelin; Dan Falkenback; Jimmie Kristensson
Journal:  PLoS One       Date:  2020-06-22       Impact factor: 3.240

5.  The impact of colectomy on the risk of cardiovascular disease among patients without colorectal cancer.

Authors:  Chin-Chia Wu; Ta-Wen Hsu; Chia-Chou Yeh; Cheng-Hung Lee; Mei-Chen Lin; Chun-Ming Chang
Journal:  Sci Rep       Date:  2020-02-19       Impact factor: 4.379

6.  Lung cancer and end-of-life care: a systematic review and thematic synthesis of aggressive inpatient care.

Authors:  Olivier Bylicki; Morgane Didier; Frederic Riviere; Jacques Margery; Frederic Grassin; Christos Chouaid
Journal:  BMJ Support Palliat Care       Date:  2019-08-31       Impact factor: 3.568

7.  Anti-tumor treatment and healthcare consumption near death in the era of novel treatment options for patients with melanoma brain metastases.

Authors:  Annemarie C Eggen; Geke A P Hospers; Ingeborg Bosma; Miranda C A Kramer; Anna K L Reyners; Mathilde Jalving
Journal:  BMC Cancer       Date:  2022-03-05       Impact factor: 4.430

Review 8.  Conceptualizing and Counting Discretionary Utilization in the Final 100 Days of Life: A Scoping Review.

Authors:  Paul R Duberstein; Michael Chen; Michael Hoerger; Ronald M Epstein; Laura M Perry; Sule Yilmaz; Fahad Saeed; Supriya G Mohile; Sally A Norton
Journal:  J Pain Symptom Manage       Date:  2019-10-19       Impact factor: 3.612

9.  Use of symptom-focused oncological cancer therapies in hospices: a retrospective analysis.

Authors:  Ulrich Kaiser; Ursula Vehling-Kaiser; Fabian Kück; Nicolae-Catalin Mechie; Ana Hoffmann; Florian Kaiser
Journal:  BMC Palliat Care       Date:  2020-09-12       Impact factor: 3.234

10.  Knowledge and use of prognostic scales by oncologists and palliative care physicians in adult patients with advanced cancer: A national survey (ONCOPRONO study).

Authors:  Raphaëlle Dantigny; Fiona Ecarnot; Guillaume Economos; Elise Perceau-Chambard; Stéphane Sanchez; Cécile Barbaret
Journal:  Cancer Med       Date:  2021-12-24       Impact factor: 4.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.